{
    "Trade/Device Name(s)": [
        "Elecsys proBNP II STAT Immunoassay",
        "Elecsys proBNP II STAT CalSet"
    ],
    "Submitter Information": "Roche Diagnostics Corp.",
    "510(k) Number": "K092649",
    "Predicate Device Reference 510(k) Number(s)": [
        "K072437",
        "K022516"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "NBC",
        "JIT"
    ],
    "Summary Letter Date": "January 4, 2010",
    "Summary Letter Received Date": "January 5, 2010",
    "Submission Date": "",
    "Regulation Number(s)": [
        "21CFR862.1117"
    ],
    "Regulation Name(s)": [
        "B-type Natriuretic Peptide Test System"
    ],
    "Analyte Class(es)": [
        "chemistry"
    ],
    "Analyte(s)": [
        "N-terminal pro-brain natriuretic peptide (NT-proBNP)"
    ],
    "Specimen Type(s)": [
        "Serum",
        "Plasma"
    ],
    "Specimen Container(s)": [
        "K2-EDTA tube",
        "K3-EDTA tube",
        "Lithium heparin tube",
        "Sodium heparin tube"
    ],
    "Instrument(s)/Platform(s)": [
        "cobas e 601 immunoassay analyzer"
    ],
    "Method(s)/Technology(ies)": [
        "Electrochemiluminescent immunoassay (ECLIA)",
        "Sandwich immunoassay"
    ],
    "Methodologies": [],
    "Submission Type(s)": [
        "Assay",
        "Calibrator"
    ],
    "Document Summary": "FDA 510(k) summary for Elecsys proBNP II STAT Immunoassay and CalSet for quantitative determination of NT-proBNP on cobas e 601 platform",
    "Indications for Use Summary": "Aid in the diagnosis of individuals suspected of congestive heart failure, risk stratification of patients with acute coronary syndrome and congestive heart failure, and assessment of increased risk of cardiovascular events and mortality in patients at risk for heart failure with stable coronary artery disease",
    "fda_folder": "Clinical Chemistry"
}